Athenex Announces Appointment of Chief Financial Officer
BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical…
News
Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET
WARREN, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
PROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a…
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support…
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease Immix Biopharma, Inc….
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference
CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech…
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021…
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical…
Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies…
Enlivex Strengthens Management Team with the Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical
Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently…
Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL,…
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address…
GeneType Multi-Test Receives Regulatory Approval for Commercial Release in USA and Australia
MELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
– Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific…
Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21
FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum
PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp.
MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…